Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and FLT3 inhibitor


Ontology type: sgo:Patent     


Patent Info

DATE

N/A

AUTHORS

Shinsuke MIZUMOTO , Takuya Matsumoto

ABSTRACT

An object of the present invention is to provide a compound and pharmaceutical composition showing superior stability and/or solubility, etc. and having superior FLT3 inhibitory activity. The present invention provides a salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide, or a crystal thereof. Since the salt or a crystal thereof has superior FLT3 inhibitory activity and shows superior physicochemical properties as drugs, such as storage stability, solubility, and so forth, it is useful for treatments of diseases or conditions relating to FLT3. The present invention also provides a pharmaceutical composition and FLT3 inhibitor containing the salt or a crystal thereof. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2471", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "Shinsuke MIZUMOTO", 
        "type": "Person"
      }, 
      {
        "name": "Takuya Matsumoto", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1182/blood-2002-02-0492", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006937015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2400812", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025757807", 
          "https://doi.org/10.1038/sj.leu.2400812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2004-07-2942", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027038954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1205332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042923053", 
          "https://doi.org/10.1038/sj.onc.1205332"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "description": "

An object of the present invention is to provide a compound and pharmaceutical composition showing superior stability and/or solubility, etc. and having superior FLT3 inhibitory activity. The present invention provides a salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide, or a crystal thereof. Since the salt or a crystal thereof has superior FLT3 inhibitory activity and shows superior physicochemical properties as drugs, such as storage stability, solubility, and so forth, it is useful for treatments of diseases or conditions relating to FLT3. The present invention also provides a pharmaceutical composition and FLT3 inhibitor containing the salt or a crystal thereof.

\"embedded

", "id": "sg:patent.US-9701644-B2", "keywords": [ "salt", "heterocyclic compound", "crystal", "pharmaceutical", "FLT3 inhibitor", "invention", "compound", "superior stability", "solubility", "inhibitory activity", "amino", "NS", "physicochemical property", "drug", "storage stability", "disease", "condition", "FLT3" ], "name": "Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and FLT3 inhibitor", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.410862.9", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-9701644-B2" ], "sdDataset": "patents", "sdDatePublished": "2019-03-07T15:32", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com.uberresearch.data.dev.patents-pipeline/full_run_10/sn-export/5eb3e5a348d7f117b22cc85fb0b02730/0000100128-0000348334/json_export_2d2c25e7.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-9701644-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-9701644-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-9701644-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-9701644-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

57 TRIPLES      14 PREDICATES      35 URIs      25 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-9701644-B2 schema:about anzsrc-for:2471
2 schema:author N44aaa58dc8374935a9c3b09e1e708bfb
3 schema:citation sg:pub.10.1038/sj.leu.2400812
4 sg:pub.10.1038/sj.onc.1205332
5 https://doi.org/10.1182/blood-2002-02-0492
6 https://doi.org/10.1182/blood-2004-07-2942
7 schema:description <p id="p-0001" num="0000">An object of the present invention is to provide a compound and pharmaceutical composition showing superior stability and/or solubility, etc. and having superior FLT3 inhibitory activity. The present invention provides a salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide, or a crystal thereof. Since the salt or a crystal thereof has superior FLT3 inhibitory activity and shows superior physicochemical properties as drugs, such as storage stability, solubility, and so forth, it is useful for treatments of diseases or conditions relating to FLT3. The present invention also provides a pharmaceutical composition and FLT3 inhibitor containing the salt or a crystal thereof.</p><p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="27.01mm" wi="74.93mm" file="US09701644-20170711-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif" orientation="portrait" inline="no"/><attachments><attachment idref="CHEM-US-00001" attachment-type="cdx" file="US09701644-20170711-C00001.CDX"/><attachment idref="CHEM-US-00001" attachment-type="mol" file="US09701644-20170711-C00001.MOL"/></attachments></chemistry></p>
8 schema:keywords FLT3
9 FLT3 inhibitor
10 NS
11 amino
12 compound
13 condition
14 crystal
15 disease
16 drug
17 heterocyclic compound
18 inhibitory activity
19 invention
20 pharmaceutical
21 physicochemical property
22 salt
23 solubility
24 storage stability
25 superior stability
26 schema:name Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and FLT3 inhibitor
27 schema:recipient https://www.grid.ac/institutes/grid.410862.9
28 schema:sameAs https://app.dimensions.ai/details/patent/US-9701644-B2
29 schema:sdDatePublished 2019-03-07T15:32
30 schema:sdLicense https://scigraph.springernature.com/explorer/license/
31 schema:sdPublisher N5cb42dca1c6b4941bbc8645355eaad01
32 sgo:license sg:explorer/license/
33 sgo:sdDataset patents
34 rdf:type sgo:Patent
35 N1aff34cb57ae49e588c172ce69f77834 schema:name Shinsuke MIZUMOTO
36 rdf:type schema:Person
37 N44aaa58dc8374935a9c3b09e1e708bfb rdf:first N1aff34cb57ae49e588c172ce69f77834
38 rdf:rest N9bedf6b0bc7b496d8db7cb4e1de27632
39 N5cb42dca1c6b4941bbc8645355eaad01 schema:name Springer Nature - SN SciGraph project
40 rdf:type schema:Organization
41 N9bedf6b0bc7b496d8db7cb4e1de27632 rdf:first Nc06c814535ce4b1e950a270e1a59ed1b
42 rdf:rest rdf:nil
43 Nc06c814535ce4b1e950a270e1a59ed1b schema:name Takuya Matsumoto
44 rdf:type schema:Person
45 anzsrc-for:2471 schema:inDefinedTermSet anzsrc-for:
46 rdf:type schema:DefinedTerm
47 sg:pub.10.1038/sj.leu.2400812 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025757807
48 https://doi.org/10.1038/sj.leu.2400812
49 rdf:type schema:CreativeWork
50 sg:pub.10.1038/sj.onc.1205332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042923053
51 https://doi.org/10.1038/sj.onc.1205332
52 rdf:type schema:CreativeWork
53 https://doi.org/10.1182/blood-2002-02-0492 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006937015
54 rdf:type schema:CreativeWork
55 https://doi.org/10.1182/blood-2004-07-2942 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027038954
56 rdf:type schema:CreativeWork
57 https://www.grid.ac/institutes/grid.410862.9 schema:Organization
 




Preview window. Press ESC to close (or click here)


...